Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:17:1-6.
doi: 10.1007/8904_2014_307. Epub 2014 Jul 6.

Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report

R M K Stewart  1 , M C Briggs, J C Jarvis, J A Gallagher, L Ranganath
Affiliations

Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report

R M K Stewart et al. JIMD Rep. 2014.

Abstract

We describe a patient with ultra-rare disease, alkaptonuria, who developed tyrosine keratopathy following nitisinone therapy of 2 mg on alternate days. His vision became impaired approximately 7 weeks following the commencement of nitisinone and ophthalmological examination at week nine showed characteristic dendritic keratopathy associated with tyrosinaemia. The corneal lesion as well as his visual symptoms normalized completely following discontinuation of nitisinone. This is the first documented report of keratopathy due to acquired tyrosinaemia due to very low-dose nitisinone.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Slit lamp examination of the eyes plus slit lamp photography showing (a) clarity of the cornea, (b) a dendritiform corneal opacity typical of tyrosine keratopathy, (c) a reduction of corneal opacity at 1 week following cessation of nitisinone and (d) no visible keratopathy at 1 year follow-up
Fig. 2
Fig. 2
(a) Itchy urticarial skin rash on nitisinone and (b) resolution of the skin rash following cessation of nitisinone
See this image and copyright information in PMC

References

    1. Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL, Anderson PD, Huizing M, Anikster Y, Gerber LH, Gahl WA. Natural history of Alkaptonuria. N Engl J Med. 2002;347:2111–2121. doi: 10.1056/NEJMoa021736. - DOI - PubMed
    1. Helliwell TR, Gallagher JA, Ranganath L. Alkaptonuria – a review of surgical and autopsy pathology. Histopathology. 2008;53:503–512. - PubMed
    1. McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type I. Drugs. 2006;66(6):743–750. doi: 10.2165/00003495-200666060-00002. - DOI - PubMed
    1. Zannoni VG, Lomtevas N, Goldfinger S. Oxidation of homogentisic acid to ochronotic pigment in connective tissue. Biochim Biophys Acta. 1969;177:94–105. doi: 10.1016/0304-4165(69)90068-3. - DOI - PubMed
    1. Goodfellow RJ, Schwartz J, Leya F. Black Aorta: a rare finding at aortic valve replacement. J Invasive Cardiol. 2005;17:165–167. - PubMed

LinkOut - more resources